JY
ALXO icon

Jeff Yass’s ALX Oncology ALXO Stock Holding History

Jeff Yass’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
123,157
-1,205,750
-91% -$2.16M ﹤0.01% 11415
2026
Q1 		$2.66M Buy
1,328,907
+1,177,880
+780% +$2.24M ﹤0.01% 5525
2025
Q4 		$171K Buy
151,027
+37,964
+34% +$57.5K ﹤0.01% 11044
2025
Q3 		$207K Sell
113,063
-50,750
-31% -$44K ﹤0.01% 10923
2025
Q2 		$68K Buy
163,813
+42,103
+35% +$21.2K ﹤0.01% 12002
2025
Q1 		$75.8K Sell
121,710
-29,910
-20% -$35.9K ﹤0.01% 11696
2024
Q4 		$253K Buy
151,620
+121,272
+400% +$186K ﹤0.01% 10187
2024
Q3 		$55.2K Buy
30,348
+5,787
+24% +$21.5K ﹤0.01% 11342
2024
Q2 		$148K Buy
24,561
+859
+4% +$10.6K ﹤0.01% 10706
2024
Q1 		$264K Sell
23,702
-15,813
-40% -$222K ﹤0.01% 9997
2023
Q4 		$588K Sell
39,515
-12,569
-24% -$119K ﹤0.01% 8259
2023
Q3 		$250K Buy
52,084
+22,675
+77% +$123K ﹤0.01% 9744
2023
Q2 		$221K Buy
29,409
+17,054
+138% +$112K ﹤0.01% 10076
2023
Q1 		$55.8K Buy
+12,355
New +$93.6K ﹤0.01% 11649
2022
Q3 		– Sell
-25,193
Closed -$294K – 13097
2022
Q2 		$204K Sell
25,193
-30,219
-55% -$329K ﹤0.01% 10580
2022
Q1 		$936K Buy
55,412
+2,542
+5% +$43.4K ﹤0.01% 7298
2021
Q4 		$1.14M Buy
52,870
+37,018
+234% +$1.6M ﹤0.01% 6952
2021
Q3 		$1.17M Sell
15,852
-6,309
-28% -$420K ﹤0.01% 7152
2021
Q2 		$1.21M Sell
22,161
-13,089
-37% -$783K ﹤0.01% 7217
2021
Q1 		$2.6M Buy
35,250
+30,068
+580% +$2.37M ﹤0.01% 5295
2020
Q4 		$447K Buy
+5,182
New +$312K ﹤0.01% 8523

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Jeff Yass's ALXO Position: Q2 2026 in Review

Jeff Yass reduced its ALX Oncology (ALXO) stake by 91% in Q2 2026, selling an estimated $2.16M and leaving 123,157 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #11415.

Jeff Yass first reported a position in ALXO in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.66M in Q1 2026. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Jeff Yass held 123,157 shares of ALX Oncology worth $255K as of Q2 2026.
  • Jeff Yass sold 1,205,750 ALX Oncology shares in Q2 2026, an estimated $2.16M.
  • ALX Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11415 holding.
  • Jeff Yass first reported a position in ALX Oncology in Q4 2020 and has held it in 21 quarters since.
  • Jeff Yass's ALX Oncology position peaked at $2.66M in Q1 2026.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.